CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases ...

"Design continued its progress through the first quarter of 2025, marked by the favorable results from our Phase 1 trial in FECD which, in combination with our biomarker studies, support advancing ...

From a product mix perspective, NRE revenues declined from the previous quarter due to the dynamic of design cycle and sales booking schedule of some projects. However, mass production, including the ...

The Fourways Review has been the voice of the community since 2003. Development in the area expanded at a rapid rate and through consistent, independent research, we kept up with readers ...

Interior Design Masters judge Michelle Ogundehin was tearful as she ... "You are setting me off now." In the quarter-final, the hopefuls were tasked with doing up two shops in Rye. Briony and Rita ...

Discover innovative architectural projects merging buildings with nature across Europe, Asia, and North America for sustainable cities.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only ...

Also read: 60 million people targeted to help Cllr keep Fourways clean Foley said his brainchild was born out of frustration with the rampant littering that seems to be becoming a trend in the ...

Hsinchu, Taiwan, R.O.C., Jul. 13, 2017 – TSMC today announced consolidated revenue of NT$213.86 billion, net income of NT$66.27 billion, and diluted earnings per share of NT$2.56 (US$0.42 per ADR unit ...

“Design continued its progress through the first quarter of 2025, marked by the favorable results from our Phase 1 trial in FECD which, in combination with our biomarker studies, support ...

Adjusted diluted earnings per share, a non-GAAP measure, for the first quarter of 2025 was $0.41, which came in at the high end of our guidance, as compared to $0.39 in the first quarter of 2024.